Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI107708

Metabolic Studies of the Third Component of Complement and the Glycine-Rich Beta Glycoprotein in Patients with Hypocomplementemia

J. A. Charlesworth, D. Gwyn Williams, E. Sherington, P. J. Lachmann, and D. K. Peters

Department of Medicine, Royal Postgraduate Medical School, London

Department of Immunology, Royal Postgraduate Medical School, London

Find articles by Charlesworth, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, London

Department of Immunology, Royal Postgraduate Medical School, London

Find articles by Williams, D. in: JCI | PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, London

Department of Immunology, Royal Postgraduate Medical School, London

Find articles by Sherington, E. in: JCI | PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, London

Department of Immunology, Royal Postgraduate Medical School, London

Find articles by Lachmann, P. in: JCI | PubMed | Google Scholar

Department of Medicine, Royal Postgraduate Medical School, London

Department of Immunology, Royal Postgraduate Medical School, London

Find articles by Peters, D. in: JCI | PubMed | Google Scholar

Published June 1, 1974 - More info

Published in Volume 53, Issue 6 on June 1, 1974
J Clin Invest. 1974;53(6):1578–1587. https://doi.org/10.1172/JCI107708.
© 1974 The American Society for Clinical Investigation
Published June 1, 1974 - Version history
View PDF
Abstract

Metabolic studies using radioiodine-labeled third component of complement (C3) and the glycine-rich β glycoprotein (GBG), a major component of the C3b-feedback pathway, were undertaken in normal subjects, in 22 patients with evidence of complement activation, and in 11 patients with various renal diseases without evidence of complement activation. In seven normal subjects GBG was found to be a rapidly metabolized protein with catabolic rates ranging from 1.7% to 2.2% of the plasma pool/h, synthesis rates from 0.14 to 0.21 mg/kg per h. and extravascular/intravascular distribution ratios from 0.81 to 1.31. In patients with reduced plasma C3, both increased C3 fractional catabolic rates and reduced C3 synthesis rates were observed, and in some patients there was evidence of increased extravascular distribution of the protein. GBG catabolism was usually increased when there was evidence of C3 activation, presumably reflecting activation of the C3b-feedback; but GBG turnover was normal or only slightly accelerated in some patients with accelerated C3 catabolism and profound hypocomplementemia, suggesting that reduced C3 synthesis had limited activation of the C3b-feedback.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1578
page 1578
icon of scanned page 1579
page 1579
icon of scanned page 1580
page 1580
icon of scanned page 1581
page 1581
icon of scanned page 1582
page 1582
icon of scanned page 1583
page 1583
icon of scanned page 1584
page 1584
icon of scanned page 1585
page 1585
icon of scanned page 1586
page 1586
icon of scanned page 1587
page 1587
Version history
  • Version 1 (June 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts